The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol


ALBAYRAK G., Korkmaz F. D. , Tozcu D., DOĞAN TURAÇLI İ.

JOURNAL OF CELLULAR BIOCHEMISTRY, cilt.120, sa.6, ss.10564-10571, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 120 Konu: 6
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1002/jcb.28342
  • Dergi Adı: JOURNAL OF CELLULAR BIOCHEMISTRY
  • Sayfa Sayıları: ss.10564-10571

Özet

ObjectivesLung cancer stands out as the most common cancer type worldwide. The most common genetic alteration detected in adenocarcinoma patients is KRAS. KRAS mutated patients still cannot get benefit from precision medicine approaches and lack a targeted therapy. Elesclomol is an investigational agent for melanoma and other malignancies. In this study, we evaluated its effect on cellular apoptosis, survival, and metastasis mechanisms on KRAS mutant A549 and Calu-1 cell lines.